HEALTHglobal
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Single source
Updated 2 hours ago
First seen March 16, 2026 23:10:16Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.